Free Trial
LON:CEL

Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Celadon Pharmaceuticals logo
GBX 5.72 -0.78 (-12.00%)
As of 03:32 AM Eastern

About Celadon Pharmaceuticals Stock (LON:CEL)

Key Stats

Today's Range
4.30
5.72
50-Day Range
3
20.80
52-Week Range
2.21
110
Volume
11,032 shs
Average Volume
291,372 shs
Market Capitalization
£3.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com

Receive CEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CEL Stock News Headlines

Celadon Pharmaceuticals (LON:CEL) Shares Up 0.8% - Still a Buy?
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Celadon Pharmaceuticals to Delist From AIM
See More Headlines

CEL Stock Analysis - Frequently Asked Questions

Celadon Pharmaceuticals' stock was trading at GBX 14 at the start of the year. Since then, CEL stock has decreased by 53.2% and is now trading at GBX 6.56.
View the best growth stocks for 2025 here
.

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Communication
Current Symbol
LON:CEL
CIK
N/A
Fax
N/A
Employees
2,780
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-4,965,636.99
Net Margins
-4,024.62%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£123,381.65
Cash Flow
GBX 2.15 per share
Price / Cash Flow
3.05
Book Value
GBX 3.80 per share
Price / Book
1.73

Miscellaneous

Free Float
N/A
Market Cap
£4.02 million
Optionable
Not Optionable
Beta
-0.26
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:CEL) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners